Generation and validation of structurally defined antibody-siRNA conjugates
Nanna AR, Kel'in AV, Theile C, Pierson JM, Voo ZX, Garg A, Nair JK, Maier MA, Fitzgerald K, Rader C. Nucleic Acids Res. 2020 Apr 29 PubMed
Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer
Blakney AK, Zhu Y, McKay PF, Bouton CR, Yeow J, Tang J, Hu K, Samnuan K, Grigsby CL, Shattock RJ, Stevens MM. ACS Nano. 2020 Apr 20. PubMed
Cationic Amphiphilic Drugs Boost the Lysosomal Escape of Small Nucleic Acid Therapeutics in a Nanocarrier-Dependent Manner
Van de Vyver T, Bogaert B, De Backer L, Joris F, Guagliardo R, Van Hoeck J, Merckx P, Van Calenbergh S, Ramishetti S, Peer D, Remaut K, De Smedt SC, Raemdonck K. ACS Nano. 2020 Apr 28;14(4):4774-4791. PubMed
Vaccination against non-mutated neoantigens induced in recurrent and future tumors
Garrido G, Schrand B, Levay A, Rabasa Capote A, Ferrantella A, Da Silva DM, D'Eramo F, Marijt KA, Zhang Z, Kwon D, Kortylewski M, Kast WM, Dudeja V, van Hall T, Gilboa E. Cancer Immunol Res. 2020 Apr 15. PubMed
Effect of inclisiran, the siRNA against PCSK9, on platelets, immune cells and immunological biomarkers – a pre-specified analysis from ORION-1
Landmesser U, Haghikia A, Leiter LA, Wright RS, Kallend D, Wijngaard P, Stoekenbroek R, Kastelein JJP, Ray KK. Cardiovasc Res. 2020 Apr 3. PubMed
Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis
Yu RZ, Collins JW, Hall S, Ackermann EJ, Geary RS, Monia BP, Henry SP, Wang Y. Nucleic Acid Ther. 2020 Apr 15. PubMed
Reverse Transcription Quantitative Polymerase Chain Reaction Methods to Support Pharmacokinetics and Drug Mechanism of Action to Advance Development of RNA Interference Therapeutics
Castellanos-Rizaldos E, Brown CR, Dennin S, Kim J, Gupta S, Najarian D, Gu Y, Aluri K, Enders J, Brown K, Xu Y. Nucleic Acid Ther. 2020 Mar 23. PubMed
Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration
Goel V, Gosselin NH, Jomphe C, Zhang X, Marier JF, Robbie GJ. Nucleic Acid Ther. 2020 Mar 12. PubMed
Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
Obici L, Berk JL, GonzĂ¡lez-Duarte A, Coelho T, Gillmore J, Schmidt HH, Schilling M, Yamashita T, Labeyrie C, Brannagan TH 3rd, Ajroud-Driss S, Gorevic P, Kristen AV, Franklin J, Chen J, Sweetser MT, Wang JJ, Adams D. Amyloid. 2020 Mar 4:1-10. PubMed
MTL-CEBPA, a small activating RNA therapeutic up-regulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multi-centre, open-label, phase I trial
Sarker D, Plummer R, Meyer T, Sodergren M, Basu B, Chee CE, Huang KW, Palmer DH, Ma YT, Evans TRJ, Spalding DR, Pai M, Sharma R, Pinato DJ, Spicer J, Hunter S, Kwatra V, Nicholls JP, Collin D, Nutbrown R, Glenny H, Fairbairn S, Reebye ...
